Ulrich Laufs
Leipzig University
Publications 504
#1Tanja B. Grammer (Heidelberg University)H-Index: 30
#2Alexander Dressel (Heidelberg University)H-Index: 6
Last.David Pittrow (TUD: Dresden University of Technology)H-Index: 35
view all 10 authors...
Guidelines for prevention of cardiovascular diseases use risk scores to guide the intensity of treatment. A comparison of these scores in a German population has not been performed. We have evaluated the correlation, discrimination and calibration of ten commonly used risk equations in primary care in 4044 participants of the DETECT (Diabetes and Cardiovascular Risk Evaluation: Targets and Essential Data for Commitment of Treatment) study. The risk equations correlate well with each other. All r...
#1Daniel LavallH-Index: 6
#2N. Jacobs (Saarland University)
Last.Ulrich LaufsH-Index: 68
view all 6 authors...
Abstract Mineralocorticoid receptor (MR) overactivation promotes cardiac fibrosis. We studied the ability of the non-steroidal MR antagonist finerenone to prevent fibrotic remodeling. In neonatal rat cardiac fibroblasts, finerenone prevented aldosterone-induced nuclear MR translocation. Treatment with finerenone decreased the expression of connective tissue growth factor (CTGF) (74±15% of control, p=0.005) and prevented aldosterone-induced upregulation of CTGF and lysyl oxidase (LOX) completely....
#1Ulrich LaufsH-Index: 68
#2Ricardo Dent (Amgen)H-Index: 13
Last.M. John Chapman (NIH: National Institutes of Health)H-Index: 78
view all 6 authors...
Eine chronische Inflammation im Rahmen von Autoimmunerkrankungen ist mit einer erhohten Rate an supraventrikularen und ventrikularen Arrhythmien vergesellschaftet, welche mit einer gesteigerten Morbiditat und Mortalitat assoziiert ist. Die Beteiligung des spezifischen Erregungsleitungssystems wird sehr haufig bei chronischen Autoimmunprozessen beobachtet, wenngleich die klinische Penetranz sehr unterschiedlich ist und therapiebedurftige Blockierungen nur selten auftreten. Fur die Pathogenese tac...
Abstract Aims Increased body mass index (BMI) contributes to cardiovascular risk and may influence efficacy of therapeutic antibodies. We investigated the effect of baseline BMI on efficacy and safety of alirocumab, a PCSK9 monoclonal antibody. Methods In a post-hoc analysis, data were pooled from 10 Phase 3 trials (n = 4975) of alirocumab vs. placebo/ezetimibe controls. Alirocumab dose was 150 mg every 2 weeks in two trials, and 75 mg with possible increase to 150 mg at 12 weeks (based on Week ...
Purpose of Review Low-density lipoprotein cholesterol (LDL-C) is one major cause of cardiovascular disease (CVD). In this review, we discuss current developments in the understanding of LDL-C as lifelong risk factor, treatment targets, and emerging approaches to reduce cardiovascular risk by lowering LDL-C.